PCVX

Vaxcyte, Inc.

• TipRanks·10/19 16:06

  Vaxcyte (PCVX) Receives a Buy from Guggenheim

• Seeking Alpha·10/19 11:30

  Vaxcyte: Vaccine Titan In The Making

• NASDAQ·10/16 09:02

  Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program Advances

• Simply Wall St·10/15 14:31

  Vaxcyte (PCVX), What Is Behind The Fresh Attention?

• NASDAQ·10/14 12:55

  Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

• Simply Wall St·10/14 12:23

  Vaxcyte Stock In Focus After Phase 3 Vaccine Trial Success

• NASDAQ·10/12 14:37

  Interesting PCVX Put And Call Options For July 2027

• TipRanks·10/12 11:46

  Cantor Fitzgerald Sticks to Their Buy Rating for Vaxcyte (PCVX)

• Dow Jones·10/12 11:08

  Vaxcyte Price Target Announced at $120.00/Share by Cantor Fitzgerald

• Benzinga·10/12 10:57

  Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target

• Benzinga·10/12 09:12

  Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'

• TipRanks·10/09 20:58

  Vaxcyte Bolsters Capital Structure with New Offerings

• Dow Jones·10/09 20:05

  Press Release: Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Convertible Senior Notes

• Benzinga·10/09 19:11

  A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally

• Benzinga·10/09 15:00

  Reported Earlier: 'Cancer Vaccines Are the N.I.H's Next Big Bet' - The New York Times